- •OCT assessed neoatherosclerosis (NA) in statin-treated patients.
- •TG-rich lipoprotein (TRL) levels were significantly higher in the NA group.
- •Apolipoprotein (apo) C3, TRL-C, and apoB levels were risk factors for NA
- •LDL-C levels were similar in the NA and non-NA group.
Abbreviations:AA (indicates Arachidonic acid), ACS (Acute coronary syndrome), Apo (Apolipoprotein), AUC (Area under the curve), CAD (Coronary artery disease), CI (Confidence interval), DES (Drug eluting stent), eGFR (estimated glomerular filtration rate), EPA (Eicosapentaenoic acid), HbA1c (Glycated hemoglobin), HDL-C (High-density lipoprotein-cholesterol), Hs-CRP (High-sensitivity C-reactive protein), LDL-C (Low-density lipoprotein-C), MACE (Major adverse cardiovascular event), MDA-LDL (Malondialdehyde-modified low-density lipoprotein), NA (Neoatherosclerosis), Non-HDL-C (Non-high-density lipoprotein cholesterol), NT-proBNP (N-terminal pro-brain natriuretic peptide), OCT (Optical coherence tomography), OR (Odds ratio), PCI (Percutaneous coronary intervention), Sd-LDL-C (Small dense LDL-C), TG (Triglyceride), TRL-C (Triglyceride-rich lipoprotein-cholesterol), TRLs (Triglyceride-rich lipoproteins)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Clinical Lipidology
- The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents.J Am Coll Cardiol. 2011; 57: 1314-1322
- Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment.Eur Heart J. 2015; 36: 2147-2159
- The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry.EuroIntervention. 2016; 12: e1366-e1374
- Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation.Circ Cardiovasc Interv. 2015; 8e001878
- Optical coherence tomography-based evaluation of in-stent neoatherosclerosis in lesions with more than 50% neointimal cross-sectional area stenosis.EuroIntervention. 2013; 9: 945-951
- Incidence, clinical presentation, and predictors of early neoatherosclerosis after drug-eluting stent implantation.Am Heart J. 2015; 170: 591-597
- Comparison of outcomes in patients with ST-segment elevation myocardial infarction discharged on versus not on statin therapy (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial).Am J Cardiol. 2014; 113: 1273-1279
- 2016 ESC/EAS guidelines for the management of dyslipidaemias.Eur Heart J. 2016; 37: 2999-3058
- Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.Curr Atheroscler Rep. 2012; 14: 1-10
- Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.JAMA. 2012; 307: 1302-1309
- Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology.Circ Res. 2016; 118: 547-563
- Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound.J Am Coll Cardiol. 2002; 39: 604-609
- In-stent neoatherosclerosis: a final common pathway of late stent failure.J Am Coll Cardiol. 2012; 59: 2051-2057
- Development of a homogeneous assay for measurement of small dense LDL cholesterol.Clin Chem. 2011; 57: 57-65
- Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease.Eur J Prev Cardiol. 2020; 27: 1091-1100
- Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.Eur Heart J. 2007; 28: 961-967
- Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation.J Am Coll Cardiol. 2012; 59: 1058-1072
- Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.Circulation. 2007; 115: 2435-2441
- Tg, Hdl Working Group of the Exome Sequencing Project NHL, Blood I, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease.N Engl J Med. 2014; 371: 22-31
- Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study.Clin Chem. 2008; 54: 1325-1330
- Apolipoprotein C-III levels and incident coronary artery disease risk: The EPIC-Norfolk PROSPECTIVE POPULATION STudy.Arterioscler Thromb Vasc Biol. 2017; 37: 1206-1212
- Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study.Lipids Health Dis. 2020; 19: 116
- Small dense low-density lipoprotein cholesterol: a residual risk for rapid progression of non-culprit coronary lesion in patients with acute coronary syndrome.J Atheroscler Thromb. 2021;
- Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD.Curr Atheroscler Rep. 2019; 21: 27
- Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.Eur Heart J. 2022; 43: 1401-1412
- Remnant lipoproteins are residual risk factor for future cardiovascular events in patients with stable coronary artery disease and on-statin low-density lipoprotein cholesterol levels <70 mg/dL.Circ J. 2019; 83: 1302-1308
- Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease.Clin Chem. 2016; 62: 593-604
- Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography.Atherosclerosis. 2019; 284: 24-30
- Apolipoprotein B and Non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients.J Am Coll Cardiol. 2021; 77: 1439-1450
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Eur Heart J. 2020; 41: 111-188
- Comparison of incidence and time course of neoatherosclerosis between bare metal stents and drug-eluting stents using optical coherence tomography.Am J Cardiol. 2012; 110: 933-939
- Quantitative and qualitative changes in DES-related neointimal tissue based on serial OCT.JACC Cardiovasc Imag. 2012; 5: 1147-1155
- Assessment of characteristics of neointimal hyperplasia after drug-eluting stent implantation in patients with diabetes mellitus: an optical coherence tomography analysis.Cardiology. 2014; 128: 34-40
- Predictors for neoatherosclerosis: a retrospective observational study from the optical coherence tomography registry.Circ Cardiovasc Imaging. 2012; 5: 660-666
- Non-fasting hypertriglyceridemia as an independent risk factor for coronary in-stent restenosis after primary bare metal stent implantation in patients with coronary artery disease.Int Heart J. 2021; 62: 970-979
- Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent.Atherosclerosis. 2015; 239: 311-317
- Comparison of Neoatherosclerosis and neovascularization between patients with and without diabetes: an optical coherence tomography study.JACC Cardiovasc Interv. 2015; 8: 1044-1052
- GLP-1 receptor agonists and coronary arteries: from mechanisms to events.Front Pharmacol. 2022; 13856111
- Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials.Front Cardiovasc Med. 2022; 91008922
- Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.J Lipid Res. 2018; 59: 1266-1275
Ethics approval and consent to participate: Written informed consent was obtained from all individuals, and the local ethics committee approved the protocol.
Consent for publication: Not applicable.
Availability of data and materials: The raw data will not be shared as the participants did not consent to this.
Author's contributions: RS, TS, and SK (Shinji Koba) contributed to the study design, manuscript preparation, data analysis, data interpretation, and critical revisions of the manuscript. TA, NM, YY, SS, HT (Hideaki Tanaka), and RM contributed to data acquisition and analysis. YO, KO, KA, KN, KS, HT (Hiroaki Tsujita), SK (Seita Kondo), and ST contributed to data acquisition. HM contributed to data analysis and interpretation. HS and TS (Toshiro Shinke) contributed to the data interpretation, critical revisions, and editing of the manuscript.
Declaration of competing interest: Shinji Koba and Toshiro Shinke received research funding from Denka Seiken Co., Ltd. and Abbott Medical. The other authors have no conflicts of interest to declare.
Funding: Shinji Koba and Toshiro Shinke received research funding from Denka Seiken Co., Ltd. and Abbott Medical. The funders had no role in this study.